Veracyte (VCYT)
(Delayed Data from NSDQ)
$22.16 USD
+0.44 (2.03%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $22.14 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
VCYT 22.16 +0.44(2.03%)
Will VCYT be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for VCYT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VCYT
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
VCYT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Medical Instruments Stocks to Buy as Industry Trends Improve
The Zacks Analyst Blog Highlights Palantir Technologies, Veracyte, PagerDuty, Roku and UiPath
5 Top-Ranked Cathie Wood Stocks to Buy Right Now
Other News for VCYT
Commit To Buy Veracyte At $12.50, Earn 16% Annualized Using Options
Veracyte files automatic mixed securities shelf
Veracyte files automatic mixed securities shelf
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines